ArticleAntibiotics (Basel, Switzerland)2021
Role of Antimicrobial Susceptibility Testing before First-Line Treatment Containing Clarithromycin for
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Empirical therapy versus tailored therapy for Helicobacter pylori infection? A systematic review.BMC infectious diseases · 2025Pooled it
- Pooled it
- Comparative Efficacy of Azithromycin and Clarithromycin in the Management of Helicobacter pylori Infection.Cureus · 2024Article
- Article
- Antibiotic Resistance andThe Korean journal of helicobacter and upper gastrointestinal research · 2023Article
- Article
- Effectiveness of 7-day triple therapy with half-dose clarithromycin for the eradication ofFrontiers in medicine · 2023Article
- Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance.Clinical microbiology reviews · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChecking
methods257 patients with
resultsEradication rates in the SGT and ET groups were 85.4% and 58.4% (
conclusionsSGT as first-line treatment improved eradication rates of TT and SET by 28.5 (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.